Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 7/20 | 0.67 |
| ▸ | DRD2 | P14416 | 6/20 | 0.57 |
| ▸ | DRD4 | P21917 | 5/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.56 |
| ▸ | DRD1 | P21728 | 3/20 | 0.56 |
| ▸ | DRD5 | P21918 | 3/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | PRCP | P42785 | 1/20 | 0.56 |
| ▸ | EBP | Q15125 | 1/20 | 0.56 |
| ▸ | HTR1A | P08908 | 1/20 | 0.56 |
| ▸ | ACHE | P22303 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7355460 | 0.93 | DRD3 (0.77) | DRD3DRD2DRD4SIGMAR1DRD1 | |
| SCHEMBL7357645 | 0.93 | DRD3 (0.77) | DRD3DRD2DRD4SIGMAR1DRD1 | |
| SCHEMBL7346632 | 0.89 | DRD3 (0.62) | DRD3DRD2DRD4SIGMAR1DRD1 | |
| SCHEMBL7354538 | 0.86 | DRD3 (0.69) | DRD3DRD2DRD4SIGMAR1DRD1 | |
| SCHEMBL7347560 | 0.83 | DRD3 (0.55) | DRD3DRD2DRD4SIGMAR1NFKB1 | |
| SCHEMBL7311359 | 0.82 | DRD3 (0.54) | DRD3DRD2DRD4SIGMAR1NFKB1 | |
| SCHEMBL7353948 | 0.80 | DRD2 (0.86) | DRD3DRD2DRD4SIGMAR1DRD1 | |
| SCHEMBL7816859 | 0.80 | DRD3 (1.00) | DRD3DRD2DRD4SIGMAR1DRD1 | |
| SCHEMBL4827438 | 0.80 | DRD2 (0.63) | DRD3DRD2SIGMAR1 | |
| SCHEMBL7352815 | 0.80 | DRD3 (0.85) | DRD3DRD2DRD4SIGMAR1DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5594024-A | ANTIDEPRESSANTS; TREATMENT OF NARCOLEPSY, SCHIZOPHRENIA, DRUG ABUSE | THE UPJOHN COMPANY (US) | 1997-01-14 | — | — | US | disclosed |
| US-5462947-A | Nervous system disorders | THE UPJOHN COMPANY (US) | 1995-10-31 | — | — | US | disclosed |
| EP-0641320-A1 | NEW CENTRALLY ACTING SUBSTITUTED PHENYLAZACYCLOALKANES | PHARMACIA & UPJOHN COMPANY (US) | 1995-03-08 | — | — | EP | disclosed |
| WO-1992018475-A2 | SUBSTITUTED PHENYLAZACYCLOALKANES AS CNS AGENTS | THE UPJOHN COMPANY (US) | 1992-10-29 | — | — | WO | disclosed |